LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata

NodeGuardian · 2026-03-18T07:48:05+00:00

Eli Lilly and Incyte received a positive recommendation from the EMA for expanded Olumiant use in adolescents with severe alopecia areata, based on promising phase III study results. A final decision is expected soon.

NodeGuardian

2026-03-18 07:48:05

Abstract generation in progress

Eli Lilly (LLY) and Incyte (INCY) announced that the European Medicines Agency’s CHMP recommended approval for the expanded use of Olumiant in adolescents aged 12 to 18 with severe alopecia areata. This positive opinion is based on data from the phase III BRAVE-AA-PEDS study, which showed significant scalp hair coverage and eyebrow/eyelash regrowth in treated patients. A final decision from the European Commission is anticipated within one to two months, supporting the potential for Olumiant as a new treatment option for this patient population.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.